Status In progress
Process STA
ID number 933

Provisional Schedule

Expected publication 21 February 2018

Project Team

Project lead Jeremy Powell

Email enquiries


Companies sponsors Janssen
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Leukaemia CARE
  Myeloma UK
Professional groups Cancer Research UK
  Royal College of Physicians
  UK Myeloma Forum


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Aspen (dexamethasone)
  Celgene (lenalidomide, pomalidomide)
  Focus Pharmaceuticals (dexamethasone)
  Hameln Pharmaceuticals (dexamethasone)
  Hospira (dexamethasone)
  Janssen (bortezomib)
  Merck, Sharp and Dohme (dexamethasone)
  Novartis (panobinostat)
  Rosemont Pharmaceuticals (dexamethasone)
General commentators Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
Relevant research groups Cochrane Haematological Malignancies Group
  Institute of Cancer Research
  Leukaemia Busters
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
17 January 2018 - 31 January 2018 Final appraisal determination
20 April 2017 Committee meeting: 2
17 March 2017 - 07 April 2017 Appraisal consultation
22 February 2017 Committee meeting: 1
20 September 2016 Invitation to participate
08 June 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance